Verastem Oncology Reports Strong Q2 2026 Growth on Pipeline Progress — Verastem, Inc.

Event summary

$25.1M in Q2 2026 revenue from AVMAPKI FAKZYNJA CO-PACK, up from $2.1M in Q2 2025.
VS-7375 Phase 2 trials enrollment expected to complete by year-end 2026.
$90M non-dilutive funding secured from Oberland Capital, with $50M at closing.
FDA Fast Track Designation granted for VS-7375 in KRAS G12D-mutated NSCLC.
Secura Bio milestone payment of $15M received in July 2026.

The big picture

Verastem Oncology is positioning itself as a key player in RAS/MAPK pathway-driven cancer treatments, with significant progress in both its commercial and pipeline efforts. The company's focus on KRAS G12D inhibition and the strategic funding from Oberland Capital highlight its commitment to advancing novel therapies. The broader industry trend of targeting specific genetic mutations in oncology is underscored by Verastem's pipeline advancements and regulatory engagements.

What we're watching

Pipeline Execution: Whether Verastem can sustain the momentum in its VS-7375 clinical trials and meet enrollment targets by year-end.
Regulatory Pathways: The pace at which regulatory approvals for AVMAPKI FAKZYNJA CO-PACK expansion into Europe and Japan will progress.
Financial Flexibility: How the $90M non-dilutive funding will impact Verastem's strategic flexibility in future financing opportunities.